2.27
Iovance Biotherapeutics Inc stock is traded at $2.27, with a volume of 15.10M.
It is up +4.13% in the last 24 hours and down -4.62% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.18
Open:
$2.2
24h Volume:
15.10M
Relative Volume:
1.02
Market Cap:
$821.41M
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-1.8455
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
+2.71%
1M Performance:
-4.62%
6M Performance:
-20.35%
1Y Performance:
-76.65%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IOVA
Iovance Biotherapeutics Inc
|
2.27 | 788.84M | 241.53M | -389.92M | -323.54M | -1.23 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
May-16-25 | Downgrade | UBS | Buy → Neutral |
May-12-25 | Downgrade | Truist | Buy → Hold |
May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
Oct-24-24 | Initiated | UBS | Buy |
Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Nov-20-23 | Initiated | Goldman | Buy |
Sep-18-23 | Reiterated | Barclays | Overweight |
May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
Oct-31-22 | Initiated | Guggenheim | Neutral |
Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
Jan-28-22 | Upgrade | Stifel | Hold → Buy |
Dec-07-21 | Resumed | Cowen | Outperform |
Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
May-19-21 | Downgrade | Stifel | Buy → Hold |
May-03-21 | Initiated | Truist | Buy |
Apr-16-21 | Initiated | Goldman | Buy |
Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-22-20 | Initiated | Mizuho | Buy |
Mar-04-20 | Initiated | Barclays | Overweight |
Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
Feb-26-20 | Reiterated | Oppenheimer | Outperform |
Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
Oct-01-19 | Initiated | Stifel | Buy |
Apr-29-19 | Initiated | Piper Jaffray | Overweight |
Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
Feb-07-19 | Initiated | Robert W. Baird | Outperform |
Dec-31-18 | Resumed | B. Riley FBR | Buy |
Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues - GlobeNewswire
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.7%What's Next? - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 4.5%Should You Sell? - MarketBeat
Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls - Yahoo Finance
How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stock2025 Price Momentum & Growth Oriented Trade Recommendations - newser.com
Will Iovance Biotherapeutics Inc. rebound enough to break evenAnalyst Downgrade & Safe Entry Trade Signal Reports - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock fits value portfoliosChart Signals & Verified Technical Signals - newser.com
Will Iovance Biotherapeutics Inc. (2LB) stock announce special dividendMarket Sentiment Report & Weekly Top Performers Watchlists - newser.com
What the Recent 11% Surge Means for Iovance Biotherapeutics Stock in 2025 - Sahm
Why Iovance Biotherapeutics Inc. (2LB) stock signals breakout potentialJuly 2025 Opening Moves & Pattern Based Trade Signal System - newser.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Iovance Biotherapeutics (IOVA) Valuation in Focus After Recent Share Price Gains - Sahm
How Iovance Biotherapeutics Inc. stock performs during Fed tightening cyclesShort Setup & Capital Efficient Trade Techniques - newser.com
Is Iovance Biotherapeutics Inc. (2LB) stock positioned for digital growth eraMarket Volume Summary & AI Enhanced Trading Alerts - newser.com
Analyzing Iovance Biotherapeutics Inc. with multi timeframe chartsJuly 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com
Volatility clustering patterns for Iovance Biotherapeutics Inc.Quarterly Market Review & Capital Efficiency Focused Strategies - newser.com
Iovance Biotherapeutics Inc Stock Analysis and ForecastBull Market Opportunities & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
What analysts say about Iovance Biotherapeutics Inc stockMoving Average Crossovers & High Return Trading Portfolio - earlytimes.in
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Is Iovance Biotherapeutics Inc 2LB a good long term investmentStock Market Trends & Access Free Tools and Start Investing - Early Times
Is Iovance Biotherapeutics Inc a good long term investmentCapital Gains Strategies & Free Hedging Tactics for Volatile Markets - Early Times
Iovance Biotherapeutics Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Iovance Biotherapeutics (NASDAQ:IOVA) Share Price Passes Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Healthcare's Convergence Accelerates as Aging Demographics Meet Breakthrough Therapies - Baystreet.ca
Assessing Iovance Biotherapeutics (IOVA) Valuation Following Key Strategic Updates and Growth Plans - Sahm
Revenue Check: Can Iovance Biotherapeutics Inc deliver consistent EPS growthTrade Entry Report & AI Enhanced Execution Alerts - خودرو بانک
Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple - MSN
Published on: 2025-09-21 02:39:03 - خودرو بانک
Buy Signal: Can Iovance Biotherapeutics Inc grow without dilutionJuly 2025 Retail & AI Enhanced Execution Alerts - khodrobank.com
Valuation Update: Will Iovance Biotherapeutics Inc benefit from AI trendsMarket Activity Recap & Weekly Return Optimization Plans - خودرو بانک
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
Kirby Daniel Gordon | Chief Commercial Officer |
Jun 05 '25 |
Buy |
1.84 |
30,000 |
55,200 |
30,000 |
Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):